Ascletis

Ascletis sees no benefit to high, fast oral GLP-1 dose titration

The latest results show a high starting dose, fast titration model provides the same weight loss and worse tolerability than more measured approaches.

Nick Paul Taylor Apr 23, 2025 7:25am

arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am

Ascletis continues obesity surge with competitive GLP-1 data

Feb 19, 2025 10:35am

Gannex posts data on NASH asset at center of trade secret row

Jan 2, 2024 9:54am

Viking accuses Chinese biotech of 'ruse' to raid trade secrets

Jan 3, 2023 6:30am

Ascletis nabs Novartis exec as CSO

Oct 8, 2019 7:25am